We recently published 10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Hit Highs. Corcept Therapeutics Inc.

The investigational cortisol modulator relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian ...

Corcept recently suffered a blow after relacorilant was rejected by the FDA for use in Cushing’s syndrome.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Shares of Corcept Therapeutics CORT were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, ...

Corcept stock rises after a Phase 3 ovarian cancer trial showed longer survival and lower death risk, even as relacorilant ...

Jan 22 (Reuters) - Corcept Therapeutics said on Thursday a late-stage trial showed its experimental drug in combination with ...

Corcept Therapeutics (CORT) stock surges after the company said its Phase 3 ROSELLA study for its ovarian cancer drug ...

Shares of Corcept Therapeutics jumped after a trial found its investigational drug helped reduce the risk of death in patients with a treatment-resistent form of ovarian cancer. Shares rose 14% to $41 ...

Corcept Therapeutics, sponsor of the ROSELLA trial, is currently evaluating relacorilant in other solid tumors, including platinum-sensitive ovarian cancer, endometrial cancer, cervical cancer, ...

Investing.com -- Corcept Therapeutics (NASDAQ:CORT) stock surged 45% Thursday after the company announced its Phase 3 trial ...

Adding elraglusib to chemotherapy significantly increases overall survival in patients with previously untreated metastatic PDAC.